Foundation For The National Institute Of Health Inc

THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND MANAGES ALLIANCES WITH PUBLIC ANDPRIVATE INSTITUTIONS IN SUPPORT OF THE MISSION OF THE NIH, THE WORLD'S PREMIER MEDICAL RESEARCH AGENCY. THE FOUNDATION, ALSO KNOWN AS THE FNIH, WORKS WITH ITS PARTNERS TO ACCELERATE BIOMEDICAL RESEARCH AND STRATEGIES AGAINST DISEASES AND HEALTH CONCERNS IN THE UNITED STATES AND ACROSS THE GLOBE. THE FNIH ORGANIZES AND ADMINISTERS RESEARCH PROJECTS; SUPPORTS EDUCATION AND TRAINING OF NEW RESEARCHERS; ORGANIZES EDUCATIONAL EVENTS AND SYMPOSIA; AND ADMINISTERS A SERIES OF FUNDS SUPPORTING A WIDE RANGE OF HEALTH ISSUES. ESTABLISHED BY CONGRESS IN 1990, THE FNIH IS A NOT-FOR-PROFIT 501(C)(3) CHARITABLE ORGANIZATION.

SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMSPROGRAM ONE - RESEARCH PROGRAMS -ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)COMBATING THE PANDEMIC WHEN DESPERATELY ILL COVID-19 PATIENTS FIRST BEGAN KNOCKING AT THE DOORS OF U.S. HOSPITALS, HEALTHCARE WORKERS FRANTICALLY SOUGHT TO DEVELOP EFFECTIVE TREATMENTS FOR THE DISEASE. ACROSS THE WORLD, INDIVIDUAL SCIENTISTS AS WELL AS RESEARCH INSTITUTIONS LAUNCHED HUNDREDS OF STUDIES TO TEST VARIOUS POTENTIAL REMEDIES. UNFORTUNATELY, MANY OF THESE STUDIES WERE TOO SMALL OR INADEQUATELY DESIGNED TO YIELD CONCLUSIVE RESULTS. MEANWHILE, A NUMBER OF UNSUBSTANTIATED REPORTS OF "EFFECTIVE" TREATMENTS FLOODED THE MEDIA, WHICH DID LITTLE TO RELIEVE THE "INFODEMIC" OVERWHELMING THE HEALTHCARE WORKERS TRYING TO HELP THESE PATIENTS.A NATIONALLY COORDINATED, FOCUSED PLAN FOR ADDRESSING THE PANDEMIC WAS CLEARLY NEEDED AND DR. FRANCIS COLLINS CALLED ON THE FNIH TO CREATE A SOLUTION. THE RESULTING ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) PARTNERSHIP WAS FORMED IN RECORD TIME IN APRIL 2020. OVER THE FOLLOWING 10 MONTHS, ACTIV REVIEWED MORE THAN 800 POTENTIAL COVID-19 TREATMENTS AND LAUNCHED 11 ROBUSTLY DESIGNED "MASTER PROTOCOL" CLINICAL TRIALS, EACH CAPABLE OF TESTING MULTIPLE DRUGS IN A RELEVANT PATIENT POPULATION AND FUNDED THROUGH NIH BY THE U.S. GOVERNMENT'S OPERATION WARP SPEED INITIATIVE. SINCE ITS INCEPTION IN APRIL 2020, THE ACTIV TRIAL NETWORKS HAVE TESTED OVER 30 THERAPIES FOR EFFECTIVENESS AGAINST COVID-19.OF THESE PROMISING LEADS, SEVERAL HAVE ALREADY REPORTED RESULTS, WITH A MAJORITY OF THE TRIALS DUE TO READ OUT BY THE FALL OF 2022. DURING 2021, DATA FROM THE ACTIV TRIALS CONTRIBUTED TO EMERGENCY USE AUTHORIZATIONS FOR THREE TREATMENTS, INCLUDING THE MONOCLONAL ANTIBODY THERAPIES FROM BRII BIOSCIENCES, ELI LILLY, AND ASTRAZENECA, AND LED TO AN IMPORTANT CHANGE IN CLINICAL PRACTICE FOR THE USE OF ANTICOAGULATION THERAPIES IN HOSPITALIZED COVID-19 PATIENTS. IMPORTANTLY, ACTIV'S PRIORITIZATION EFFORTS MEANT THAT VALUABLE RESOURCES MONEY, LABORATORY SPACE, HEALTHCARE WORKERS' TIME, AND PATIENTS' HOPES WERE FOCUSED ON THERAPIES LIKELY TO SUCCEED AS COVID-19 TREATMENTS.ACTIV, WHICH INCLUDES EIGHT U.S. GOVERNMENT AGENCIES, FOUR NONPROFIT ORGANIZATIONS, AND 20 INDUSTRY PARTNERS, STANDS OUT AS PERHAPS THE MOST REMARKABLE COLLABORATION TO ARISE FROM THE COVID-19 RESPONSE. ITS FORMATION RELIED ON THE FNIH'S PROVEN PARTNERSHIP MODEL ENGAGE PEOPLE AND ORGANIZATIONS WITH DIVERSE KNOWLEDGE, UNIQUE CAPABILITIES, AND DISTINCT VIEWPOINTS AND CREATE AN ENVIRONMENT BASED ON OBJECTIVE SCIENCE WHERE TRUST AND THE EXCHANGE OF NEW IDEAS CAN THRIVE WHILE ACHIEVING ITS GOALS WITH UNPRECEDENTED SCALE AND SPEED. IT'S A BLUEPRINT THAT THE FNIH WILL CONTINUE TO FOLLOW TO TACKLE A HOST OF DIFFICULT BIOMEDICAL CHALLENGES STEMMING FROM THE CURRENT PANDEMIC AND MANY FUTURE CHALLENGES TO HUMAN HEALTH. TRACEIN EARLY 2020, SCIENTISTS AT THE NIH AND AROUND THE WORLD QUICKLY HAD SEQUENCED THE NEW SARS-COV-2 VIRUS AND HAD BEGUN TO CREATE EFFECTIVE TOOLS FOR STOPPING IT. BUT THEN CAME THE BETA VARIANT. GAMMA, DELTA, AND, MOST RECENTLY, OMICRON VARIANTS FOLLOWED. EACH SUCCESSIVE WAVE OF THE CORONAVIRUS CAUSED DEATH AND DISRUPTION ACROSS THE GLOBE AND THREATENED TO DIMINISH THE EFFECTIVENESS OF NEWLY AVAILABLE COVID-19 VACCINES AND THERAPIES.THE URGENCY OF TRACKING AND STUDYING THESE VARIANTS BECAME PAINFULLY CLEAR. WHILE A VARIETY OF PLATFORMS WERE AND CONTINUE TO BE USED BY DIFFERENT COUNTRIES TO SEQUENCE AND SHARE VIRUS DATA, THE FNIH AND NIH RECOGNIZED EARLY ON THAT A COORDINATED, GLOBAL PERSPECTIVE IS ESSENTIAL TO UNDERSTAND THE EVOLUTION OF THE VIRUS AND THE IMPACT OF VARIANTS ON THERAPEUTICS AND VACCINES. IN JANUARY 2021, THE FNIH CONVENED GOVERNMENT AGENCIES, ACADEMICS, AND PRIVATE PARTNERS TO ESTABLISH THE ACTIV TRACKING RESISTANCE AND CORONAVIRUS EVOLUTION (TRACE) INITIATIVE. THROUGH GENOMIC SURVEILLANCE, DATA SHARING, AND ASSESSMENTS OF TREATMENT RESPONSES TO NEW VIRUS STRAINS, TRACE STANDARDIZES AND CONSOLIDATES DATA FROM GENETIC DATABASES WORLDWIDE TO MONITOR AND TEST COVID-19 VARIANTS. TRACE ALSO ASSESSES VACCINE AND THERAPEUTIC RESISTANCE AND EVALUATES THE IMPACT OF GENETIC VARIATION ON VIRAL BIOLOGY AND ON THE CLINICAL APPROACHES FOR PREVENTING AND TREATING ILLNESS. TRACE HAS SUCCESSFULLY COMPILED ALL OF THIS CRITICAL INFORMATION INTO ONE CLEAR, PUBLICLY ACCESSIBLE PLATFORM AT THE NIH'S NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES AND IS RAPIDLY SHARING DATA ON COVID-19 VARIANTS WITH THE ENTIRE GLOBAL SCIENTIFIC COMMUNITY. THE BESPOKE GENE THERAPY CONSORTIUMRARE DISEASES ARE DEFINED IN THE U.S. AS THOSE THAT AFFECT FEWER THAN 200,000 PEOPLE WITH SOME AFFLICTING AS FEW AS 10 INDIVIDUALS IN THE WORLD. BUT COLLECTIVELY THESE DISEASES ARE RESPONSIBLE FOR WIDESPREAD HARM. SOME 25 TO 30 MILLION AMERICANS, AS WELL AS THEIR FAMILIES AND COMMUNITIES, SUFFER FROM THE APPROXIMATELY 7,000 RARE DISEASES KNOWN TODAY, WITH FEW EFFECTIVE TREATMENTS. ONE TYPE OF TREATMENT HAS EMERGED THAT OFFERS HOPE: GENE THERAPY, A PROCESS THAT REPLACES DEFECTIVE GENES THAT CAUSE DISEASE WITH FUNCTIONAL ONES. WHILE GENE THERAPIES HAVE BEEN SUCCESSFULLY USED TO TREAT COMMON GENETIC DISEASES, THEY CAN ALSO BE TAILORED (OR "BESPOKE") FOR MUCH SMALLER POPULATIONS. DEVELOPING THESE THERAPIES, HOWEVER, IS COMPLEX AND OFTEN EXPENSIVE, AND SMALL PATIENT POPULATIONS MAKE IT CHALLENGING TO GET AN ADEQUATE RETURN ON INVESTMENT IN THE DEVELOPMENT PROCESS. THE BESPOKE GENE THERAPY CONSORTIUM (BGTC) PROMISES TO CHANGE THE PLAYING FIELD FOR GENE THERAPY DEVELOPMENT. LAUNCHED IN LATE 2021 BY THE FNIH, NIH, AND FDA, THE BGTC AIMS TO GENERATE A STANDARDIZED "PLUG-AND-PLAY" TEMPLATE THAT MAKES IT EASIER TO DEVELOP NEW GENE THERAPIES. RATHER THAN CREATING A CUSTOM THERAPY FOR EACH DISEASE FROM SCRATCH, DEVELOPERS COULD SOON BE ABLE TO USE AND REUSE THIS COMMON TEMPLATE TO PRODUCE THERAPIES MORE QUICKLY AND AT LOWER COST. THE BGTC IS THE LATEST INITIATIVE TO EMERGE FROM THE FNIH'S HIGHLY SUCCESSFUL ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAM. BUILDING ON THE AMP COLLABORATION MODEL, THE BGTC PROGRAM BRINGS TOGETHER 30 PUBLIC AND PRIVATE SECTOR ORGANIZATIONS, INCLUDING MANY RARE DISEASE PATIENT GROUPS, TO SUPPORT A SERIES OF RESEARCH PROJECTS AND CLINICAL TRIALS INTENDED TO REFINE AND STANDARDIZE TRIAL DESIGN, REGULATORY EVALUATION, AND MANUFACTURING PROCESSES, ENABLING THE FIELD TO DELIVER MORE VIABLE TREATMENTS FOR RARE DISEASES TO MORE PATIENTS.ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAMSTHE FNIH LAUNCHED THE FIRST THREE ACCELERATING MEDICINES PARTNERSHIP PROGRAMS TOGETHER WITH THE NIH IN 2014. FOCUSED ON ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND RHEUMATOID ARTHRITIS AND LUPUS, THE FIRST AMP PROGRAMS GENERATED GENOMIC AND MOLECULAR DATA AND ANALYTICAL APPROACHES THAT HAVE SUBSTANTIALLY ADVANCED OUR UNDERSTANDING OF DRUG TARGETS IN THESE DISEASES. THESE THREE PARTNERSHIPS HAVE PROVED SO SUCCESSFUL THAT EACH HAS NOT ONLY PRODUCED FOLLOW-ON EFFORTS THAT CONSIDERABLY EXPAND THEIR ORIGINAL RESEARCH AGENDAS, BUT THEY HAVE ALSO INSPIRED COMPLETELY NEW AMP PROGRAMS IN PARKINSON'S DISEASE, SCHIZOPHRENIA, AND GENE THERAPIES.ACCELERATING MEDICINES PARTNERSHIP AND AMP ARE REGISTERED SERVICE MARKS OF THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.NON-INVASIVE BIOMARKERS OF METABOLIC LIVER DISEASE (NIMBLE)NON-ALCOHOLIC STEATOHEPATITIS (NASH) IS A SERIOUS LIVER DISEASE ESTIMATED TO AFFECT BETWEEN 9 AND 15 MILLION PEOPLE IN THE U.S. THE DISEASE OFTEN REMAINS UNDIAGNOSED IN ITS EARLY STAGES AND CAN REQUIRE A LIVER TRANSPLANT OR CAUSE LIVER CANCER AND ULTIMATELY DEATH. CURRENTLY, DIAGNOSING EARLY-STAGE NASH REQUIRES A LIVER BIOPSY, A PAINFUL, INVASIVE, AND EXPENSIVE PROCESS.IN NOVEMBER 2021, THE FNIH BIOMARKERS CONSORTIUM RELEASED THE INITIAL RESULTS FROM ITS NIMBLE PROJECT, WHICH SEEKS TO ASSESS THE SUITABILITY OF SEVERAL NON-INVASIVE, BLOOD-BASED BIOMARKERS FOR USE IN CLINICAL TRIALS OF TREATMENTS FOR NASH. SEVERAL OF THESE BIOMARKERS DID A BETTER JOB OF IDENTIFYING PATIENTS AT RISK OF DEVELOPING NASH OR PROGRESSING TO CIRRHOSIS THAN CURRENT STANDARD TESTS AND COMPARED FAVORABLY WITH THE DIAGNOSTIC PERFORMANCE OF LIVER BIOPSY, THE CURRENT REFERENCE STANDARD. ALTHOUGH FURTHER CONFIRMATORY STUDY MAY BE REQUIRED, THE NEW BIOMARKERS EXAMINED BY NIMBLE COULD POTENTIALLY REPLACE THE NEED FOR PATIENTS WHO HAVE OR WHO MAY BE AT RISK FOR NASH TO UNDERGO BIOPSIES. IF APPROVED BY THE FDA, TESTS USING THESE NEW MARKERS COULD ENABLE EARLY AND ACCURATE DIAGNOSIS OF AT-RISK PATIENTS, IMPROVING THE QUALITY OF CARE, ACCELERATING DRUG DEVELOPMENT, AND REDUCING THE BURDEN IMPOSED BY CURRENT CLINICAL CARE PRACTICES.

SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMSPROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - ONE OF THE MANY WAYS THE FNIH ACCELERATES PROGRESS IS THROUGH INVESTMENT IN THE CREATIVITY OF EXCEPTIONAL SCIENTISTS. THE ORGANIZATION BESTOWS THREE PRIZES EACH YEAR TO RECOGNIZE OUTSTANDING PARTNERS AND CONTRIBUTORS TO ADVANCING BIOMEDICAL RESEARCH. 2021 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCESTHE LURIE PRIZE IN BIOMEDICAL SCIENCES IS AN ANNUAL AWARD GIVEN TO PROMISING YOUNGER INVESTIGATORS WHO HAVE ACHIEVED GROUNDBREAKING ADVANCES IN BIOMEDICAL SCIENCE. THE PRIZE IS MADE POSSIBLE BY A GENEROUS GIFT FROM NOTED PHILANTHROPIST AND FNIH HONORARY BOARD MEMBER ANN LURIE. IN 2021, THE FNIH HONORED XIAOWEI ZHUANG, PH.D., FOR HER REVOLUTIONARY WORK DEVELOPING SUPER-RESOLUTION MICROSCOPY AND GENOME-SCALE IMAGING THAT REVEALED NEW SPATIAL AND FUNCTIONAL ORGANIZATIONS OF MOLECULES AND CELLS. DR. ZHUANG'S INNOVATIVE WORK WITH MICROSCOPY HAS ENABLED RESEARCHERS TO VISUALIZE WITH HIGH RESOLUTION THE POSITIONING OF AND INTERACTIONS BETWEEN MOLECULES IN A CELL, AS WELL AS THE SPATIAL ORGANIZATION OF DISTINCT TYPES OF CELLS IN TISSUES. HER DISCOVERIES HAVE MADE A SIGNIFICANT IMPACT ACROSS THE FIELD OF BIOLOGY, WITH SEMINAL APPLICATIONS TO CELL BIOLOGY.DR. ZHUANG IS A PROFESSOR AT HARVARD UNIVERSITY, A HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR, AND CO-FOUNDER OF THE LIFE SCIENCES COMPANY VIZGEN.TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTSTHE TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTS WAS ESTABLISHED IN 2018 TO HIGHLIGHT THE ESSENTIAL ROLE OF EARLY CAREER CLINICIAN-SCIENTISTS WHOSE RESEARCH HAS LED OR HAS THE POTENTIAL TO LEAD TO INNOVATIONS IN PATIENT CARE.IN 2021, PIRO LITO, M.D., PH.D., ASSOCIATE MEMBER AND ATTENDING PHYSICIAN AT MEMORIAL SLOAN KETTERING CANCER CENTER, WAS AWARDED THE PRIZE FOR CATALYZING BREAKTHROUGHS IN THE UNDERSTANDING OF ONCOPROTEIN SIGNALING AND THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES FOR CANCERS DRIVEN BY THE MUTANT KRAS PROTEIN.WORKING AT THE INTERFACE OF BASIC RESEARCH AND CLINICAL PRACTICE, DR. LITO STUDIES HOW MUTATED PROTEINS DRIVE TUMOR GROWTH. HE IS PARTICULARLY INTERESTED IN A PROTEIN CALLED KRAS, WHICH IS COMMONLY MUTATED IN LUNG, COLORECTAL, AND PANCREATIC CANCERS. DR. LITO HAS UNCOVERED HOW MUTANT KRAS TRANSITIONS BETWEEN ITS ACTIVE AND INACTIVE STATES IN CANCER CELLS AND, BY EXPOSING VULNERABLE EVENTS DURING THIS TRANSITION, HE HAS MADE KEY CONTRIBUTIONS TO THE DEVELOPMENT OF NOVEL CANCER THERAPIES THAT ARE CURRENTLY IN CLINICAL TRIALS.FUNDING FOR THE TRAILBLAZER PRIZE IS PROVIDED BY THE GALLIN FUND AT THE FNIH.CHARLES A. SANDERS, M.D., PARTNERSHIP AWARDEACH YEAR, THE FNIH BESTOWS THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD TO RECOGNIZE PEOPLE OR ORGANIZATIONS THAT HAVE MADE PARTICULARLY SIGNIFICANT CONTRIBUTIONS TO THE FOUNDATION'S EFFORTS TO BUILD, IMPLEMENT, AND NURTURE PUBLIC-PRIVATE PARTNERSHIPS IN SUPPORT OF THE MISSION OF THE NIH.IN 2021, THE FNIH PRESENTED THE PARTNERSHIP AWARD TO JANSSEN RESEARCH & DEVELOPMENT, LLC, AND TO THE EIGHT CO-CHAIRS OF THE ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) WORKING GROUPS.JANSSEN RESEARCH & DEVELOPMENT, LLC, HAS BEEN AN EXEMPLARY PARTNER AND LEADER ACROSS MANY FNIH PROGRAMS, INCLUDING ACTIV, SEVERAL ACCELERATING MEDICINES PARTNERSHIPS, THE BIOMARKERS CONSORTIUM, THE PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT), AND THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI). THE MANY JANSSEN SCIENTISTS WHO HAVE PARTICIPATED IN THESE PARTNERSHIPS HAVE CONSISTENTLY PROMOTED A HIGHLY COLLEGIAL, COLLABORATIVE APPROACH TO PROBLEM-SOLVING WITH AN EMPHASIS ON TEAMWORK AND TRANSPARENT COMMUNICATION THAT ENABLES OPEN, PRECOMPETITIVE SCIENCE.IN SUPPORT OF FINDING THERAPEUTICS AND VACCINES TO COMBAT COVID-19, THE ACTIV WORKING GROUP CO-CHAIRS SPENT COUNTLESS HOURS COLLABORATING WITH THE FNIH AND NIH TO DESIGN STRATEGIES FOR COMBATING THE COVID-19 PANDEMIC AND EXECUTE THEM WITH UNPRECEDENTED SPEED. THEY PARTICIPATED IN HUNDREDS OF MEETINGS, REPORTING REGULARLY TO THE ACTIV LEADERSHIP TEAM, AND DEVOTED VALUABLE TIME AND EFFORT TO IDENTIFY OPPORTUNITIES FOR AND HELP RESOLVE CHALLENGES TO THE PARTNERSHIP. THEIR ALL-OUT EFFORTS WERE ESSENTIAL TO ENABLING ACTIV TO NAVIGATE THE RAPIDLY CHANGING NATURE OF THE THREATS TO GLOBAL HUMAN HEALTH POSED BY SARS-COV-2.THE CO-CHAIRS OF THE ACTIV WORKING GROUPS:CHRISTINE M. COLVIS, PH.D., DIRECTOR OF DRUG DEVELOPMENT PARTNERSHIP PROGRAMS, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIHELIZABETH DESROSIERS, M.S., P.M.P., EXECUTIVE DIRECTOR OF CLINICAL SCIENCES AND STUDY MANAGEMENT AT MERCK & CO., INC.ERIC HUGHES, M.D., PH.D., GLOBAL DEVELOPMENT UNIT HEAD OF IMMUNOLOGY, HEPATOLOGY AND DERMATOLOGY, AND CHI-NOVARTISKATHRIN JANSEN, PH.D., SENIOR VICE PRESIDENT AND HEAD OF VACCINE RESEARCH AND DEVELOPMENT AT PFIZERMICHAEL KURILLA, M.D., PH.D., DIRECTOR, DIVISION OF CLINICAL INNOVATION, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIHDOUGLAS LOWY, M.D., PRINCIPAL DEPUTY DIRECTOR, NATIONAL CANCER INSTITUTE (NCI) AT NIHSARAH READ, M.D., DEPUTY DIRECTOR, DIVISION OF AIDS, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) AT NIH JOHN YOUNG, PH.D., GLOBAL HEAD OF INFECTIOUS DISEASES AND VICE PRESIDENT AT ROCHEFUNDING FOR THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD IS PROVIDED BY THE CHARLES A. SANDERS LEGACY FUND AT THE FNIH.EVENTS AND EDUCATIONTHE MEETINGS AND EVENTS DEPARTMENT CONCEPTUALIZES, PLANS, EXECUTES AND EVALUATES HIGH-QUALITY, PRODUCTIVE, INNOVATIVE AND ECONOMICAL CONVENINGS THAT ADVANCE THE ORGANIZATION'S MISSION. THESE CONVENINGS INCLUDE, BUT ARE NOT LIMITED TO, RESEARCH PROJECT TEAM MEETINGS AND CONFERENCES, DONOR STEWARDSHIP LECTURES AND SYMPOSIA AND SPECIAL EVENTS. THE DEPARTMENT OVERSEES THE MANAGEMENT OF FNIH HIGHLY RESPECTED AWARDS AND PRIZES. SOME OF THE FNIH'S MARQUEE EVENTS IN 2021 INCLUDED: THE FNIH AWARDS CEREMONY, THE CANCER STEERING COMMITTEE'S ANNUAL SYMPOSIUM, AND THE GENECONVENE GLOBAL COLLABORATIVE WEBINARS SERIES.THE FNIH SUPPORTS A NUMBER OF EDUCATIONAL AND TRAINING OPPORTUNITIES AT NIH, RANGING FROM HIGH SCHOOL TO POSTGRADUATE FELLOWSHIPS AND TRAINING. MANY OF THESE FELLOWSHIPS AND TRAININGS ARE ESTABLISHED BY INDIVIDUALS WHO SEEK TO SUPPORT THE NEXT GENERATION OF SCIENTISTS. EXAMPLES INCLUDE:- THE JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH AND POLICY SUPPORTS INTRAMURAL RESEARCH TRAINING AWARDS FOR DESERVING YOUNG SCHOLARS IN THE NIH INTRAMURAL TRAINING PROGRAM.- THE DEAN R. O'NEILL RENAL CELL CANCER RESEARCH FUND AND THE DR. EDWARD T. RANCIC MEMORIAL FUND FOR CANCER RESEARCH JOINTLY SUPPORT A FELLOW IN THE LABORATORY OF DR. RICHARD CHILDS AT THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE TO EXPLORE TREATMENTS FOR RENAL CELL CARCINOMA.- THE ESTATE OF SALLIE ROSEN KAPLAN ESTABLISHED THE SALLIE ROSEN KAPLAN POSTDOCTORAL FELLOWSHIP FOR WOMEN SCIENTISTS IN CANCER RESEARCH (SRK FELLOWSHIP). THE SRK FELLOWSHIP IS A HIGHLY COMPETITIVE, UNPAID, ANNUAL, ONE-YEAR PROGRAM THAT PROVIDES ADDITIONAL MENTORING OPPORTUNITIES, NETWORKING, SEMINARS AND WORKSHOPS TO FEMALE NATIONAL CANCER INSTITUTE POSTDOCTORAL FELLOWS TO HELP THEM PREPARE FOR THE COMPETITIVE JOB MARKET AND HELP THEM TO TRANSITION TO INDEPENDENT RESEARCH CAREERS.

SEE SCHEDULE O, PROGRAM THREE, PATIENT SUPPORT PROGRAM/CAPITAL PROJECTPROGRAM THREE - PATIENT SUPPORT PROGRAM/CAPITAL PROJECT -FILLING A NEED OF THE NATION'S LEADING RESEARCH CENTERAT THE NIH CLINICAL CENTER THE NATION'S PREMIER HOSPITAL SOLELY DEVOTED TO CLINICAL INVESTIGATION PATIENTS ARE CONSIDERED "ACTIVE PARTNERS IN MEDICAL DISCOVERY," PARTICIPATING IN EXPERIMENTAL TRIALS CARRIED OUT BY NIH INSTITUTES TO RECEIVE TREATMENT FOR THEIR CONDITIONS AND ULTIMATELY BENEFIT SCIENTIFIC PROGRESS. THE EXTENSIVE LIST OF RESEARCH BREAKTHROUGHS COMING OUT OF THE NIH CLINICAL CENTER INCLUDES THE FIRST CURES FOR CHILDHOOD LEUKEMIA AND HODGKIN'S DISEASE USING CHEMOTHERAPY, THE FIRST BLOOD TESTS FOR AIDS AND HEPATITIS, AND THE FIRST GENE THERAPY, TO NAME JUST A FEW. TO SUPPORT SUCH RESOURCE-INTENSIVE ENDEAVORS, THE FNIH ESTABLISHED THE CLINICAL CENTER IN-KIND DRUG DONATION PROGRAM TO DONATE PHARMACEUTICALS TO THE NIH CLINICAL CENTER. THE PROGRAM, WHICH HAS PROVIDED NEARLY $16 MILLION IN DRUGS AND THERAPEUTICS TO THE NIH SINCE 2008, WAS SUPPORTED IN 2019 BY A MAJOR GIFT FROM HORIZON THERAPEUTICS PLC. "THE GENEROSITY OF THE PROGRAM HAS BEEN A MAJOR BOON TO OUR PATIENTS AND OUR PROGRAM," SAYS DR. STEVEN HOLLAND, DIRECTOR, DIVISION OF INTRAMURAL RESEARCH AT NIAID.